Medical Crossfire®: How Are We Personalizing Integration of ICIs and Targeted Therapies to Optimize Outcomes in Endometrial Cancer?

Release Date: June 4, 2022

Expiration Date: July 14, 2022

Activity Overview

This educational activity is an archive of the live virtual presentation held on June 3, 2022.

For more information about this educational activity, the faculty, and disclosures, please click here.

Target Audience

This educational program is directed toward medical oncologists, gynecologic oncologists, pathologists, radiation oncologists, and surgical oncologists involved in the treatment and management of endometrial cancer. Obstetrician/gynecologists, nurses, physician assistants, fellows, residents and other healthcare professionals with an interest in endometrial cancer will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate the rationale for the use genetic testing strategies in the management of endometrial cancer through biomarker-based decision-making
• Summarize the key results of clinical trials involving emerging treatments and combinations of therapy in patients with endometrial cancer, as guided by biomarkers and genomic data
• Describe relevant supportive measures in the timely detection and management of potential treatment-related adverse events with therapies for endometrial cancer
• Explain the most efficient uses of biomarker-based therapy alongside other relevant evaluation strategies to formulate personalized treatment plans in patients with endometrial cancer

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.